• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Wall Street Beat

Ex pharma execs first to be charged in generic drug pricing case

December 15, 2016 By Sarah Faulkner

Former Heritage Pharmaceuticals CEO Jeffrey Glazer and ex-president Jason Malek were hit yesterday with the 1st criminal charges from a 2-year federal investigation in an ongoing generic drug pricing case. The 2 former executives were charged by federal authorities with price collusion for doxycycline hyclate, a widely used antibiotic, and a diabetes therapy called glyburide […]

Filed Under: Featured, Legal News, Pharmaceuticals, Wall Street Beat Tagged With: Heritage Pharmaceuticals, Mylan, Teva Pharmaceuticals, U.S. Justice Dept.

Baxter to put up $625m for Claris Injectables generics biz

December 15, 2016 By Sarah Faulkner

Bax

Baxter (NYSE:BAX) said today that acquired Claris Lifesciences (BOM:533288) subsidiary Claris Injectables for $625 million. The deal is expected to close in the 2nd half of next year. Deerfield, Ill.-based Baxter said it plans to pay for the acquisition with cash on hand, debt or a combination. Baxter anticipates launching 7 to 9 new products […]

Filed Under: Featured, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Baxter International, Claris Lifesciences

BD launches high volume syringe for biologics

December 15, 2016 By Sarah Faulkner

Becton Dickinson

Becton Dickinson (NYSE:BDX) said today that it launched its BD Neopak 2.25 milliliter prefillable glass syringe designed for high-volume injection of biologics. The Franklin Lakes, N.J.-based company said that its prefillable glass syringe was developed to reduce drug degradation and aggregation between the container and therapeutic. The high volume syringe is commercially available in the […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Technology, Wall Street Beat Tagged With: Becton Dickinson

TiGenix IPO raises $36m

December 15, 2016 By Sarah Faulkner

TiGenix IPO raises $36m

TiGenix (EBR:TIG) said today that it raised $36 million in an initial public offering from the sale of 2.3 million American depository shares, representing 46 million ordinary shares, at $15.50 apiece. The biopharmaceutical company plans to list on the NASDAQ exchange under the “TIG” symbol by Dec. 15. It is listed on the Euronext Brussels under the same symbol. […]

Filed Under: Featured, Initial Public Offering (IPO), Pharmaceuticals, Stem Cells, Wall Street Beat Tagged With: Takeda Pharmaceutical Co, TiGenix

AARP report details increase in brand name drug prices

December 14, 2016 By Sarah Faulkner

AARP report details increase in brand name drug prices

The AARP Public Policy Institute released a report today showing that 2015 was the 4th straight year of double-digit average annual increases for widely used brand name drugs. The nonprofit organization also concluded that prices for brand name drugs increased almost 130 times faster than the 0.1% general inflation rate in 2015. The report, which […]

Filed Under: Featured, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Valeant Pharmaceuticals

Eli Lilly, Express Scripts offer insulin discount program

December 14, 2016 By Sarah Faulkner

Eli Lilly

Eli Lilly (NYSE:LLY) said it is teaming up with pharmacy benefit manager Express Scripts (NSDQ:ESRX) to offer discounts on the US pharma giant’s insulin products for uninsured patients and people with high-deductible insurance plans. The program will begin January 1, 2017 and will cover Lilly’s insulins Humalog, Humulin, and the biologic Basaglar. Lilly said it anticipates the program […]

Filed Under: Diabetes, Featured, Wall Street Beat Tagged With: CVS Health, Eli Lilly & Co., Express Scripts, Novo Nordisk, Sanofi-Aventis

FDA approves first bioresorbable scaffold with autologous cells for cartilage repair

December 14, 2016 By Sarah Faulkner

vericel

Vericel Corp (NSDQ:VCEL) shares soared 56% today after the Cambridge, Mass.-based company said the FDA approved its bioresorbable scaffold for cartilage repair. The product, Maci, is the 1st FDA-approved implant to use healthy cartilage tissue from a patient’s own knee to grow cells on the scaffold. “Different cartilage defects require different treatments, so therapy must be […]

Filed Under: Featured, Food & Drug Administration (FDA), Orthopedics, Regulatory/Compliance, Stem Cells, Surgical, Wall Street Beat Tagged With: Vericel Corp

Actelion, Sanofi in talks after J&J backs out of negotiations

December 14, 2016 By Sarah Faulkner

Actelion, J&J re-enter takeover negotations

Actelion (VTX:ATLN) and Sanofi (NYSE:SNY) are reportedly in talks to reach a takeover deal after Johnson & Johnson (NYSE:JNJ) said yesterday that it has closed negotiations with the Swiss biotech. J&J and Actelion have been in informal talks for nearly 2 months and the US company has made an offer valued at 250 Swiss francs per share. J&J said yesterday […]

Filed Under: Featured, Mergers & Acquisitions, Respiratory, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson, Sanofi-Aventis

BioDelivery’s topical gel for diabetic neuropathy fails in phase IIb trial

December 13, 2016 By Sarah Faulkner

BioDelivery Sciences International

BioDelivery Sciences International (NSDQ:BDSI) said today that its clonidine topical gel for pain relief in patients with diabetic neuropathy failed in a phase IIb clinical trial. Raleigh, N.C.-based BioDelivery will halt any further development of the painkiller. In the phase IIb clinical trial, BioDelivery’s topical gel did not demonstrate a statistically significant difference in pain relief […]

Filed Under: Clinical Trials, Diabetes, Featured, Pain Management, Wall Street Beat Tagged With: BioDelivery Sciences International, Endo Pharmaceuticals

Adherium’s smart inhaler tech chosen for EU mobile health program

December 12, 2016 By Sarah Faulkner

adherium

Adherium Ltd. (ASK:ADR) said today that its Smartinhaler was chosen for the myAirCoach program as a part of the European Union’s Horizon 2020 Framework for Research and Innovation. The Horizon 2020 program is the largest EU research and innovation program ever established, with €80 billion (nearly $85 billion) of funding available from 2014 until 2020. The […]

Filed Under: Drug-Device Combinations, Featured, mHealth (Mobile Health), Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Adherium, AstraZeneca plc, GlaxoSmithKline plc

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 186
  • Page 187
  • Page 188
  • Page 189
  • Page 190
  • Interim pages omitted …
  • Page 193
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS